RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Concert Pharmaceuticals Stock

Concert Pharmaceuticals P/S 2024

Concert Pharmaceuticals P/S

8.89

Ticker

CNCE

ISIN

US2060221056

WKN

A1XEAC

As of Dec 30, 2024, Concert Pharmaceuticals's P/S ratio stood at 8.89, a 0% change from the 0 P/S ratio recorded in the previous year.

The Concert Pharmaceuticals P/S history

Concert Pharmaceuticals Aktienanalyse

What does Concert Pharmaceuticals do?

Concert Pharmaceuticals Inc was founded in 2006 and is based in Lexington, Massachusetts. The company is engaged in the discovery and development of innovative drugs for the treatment of serious diseases. The goal is to explore and bring to market novel therapeutic approaches to help people with medical needs. The company has a unique business model that focuses on the use of patented deuterosome technologies and other proprietary methods. These technologies allow Concert Pharmaceuticals to modify and alter the properties of existing drugs. This enables the development of new products that either have higher efficacy or produce fewer adverse effects in patients. One of Concert Pharmaceuticals' key areas is neurological disorders. Here, the company focuses its research on the treatment of diseases such as Alzheimer's, schizophrenia, depression, and pain. In addition, Concert Pharmaceuticals also has projects in other areas, such as the treatment of respiratory diseases, cancer, or metabolic disorders. One of the best-known products of Concert Pharmaceuticals is the drug CTP-543 for the treatment of alopecia areata or patchy hair loss. The condition, which causes sudden and massive hair loss, can be very distressing and poses a major challenge, as there is currently no effective treatment method known. CTP-543 was designated as an orphan drug by the FDA (Food and Drug Administration) in the United States in 2020. This means that it is a drug that is used to treat a rare disease and is financially supported by the FDA. The company hopes that the medication will soon be available on the market and can help those affected to improve their quality of life. Concert Pharmaceuticals also has a collaboration with Celgene Corporation, an internationally active biotechnology company. Together, they aim to develop drugs that can help in the treatment of cancer. This collaboration is intended to accelerate scientific and technological advancements. The goal is to help patients faster and more effectively. Overall, Concert Pharmaceuticals employs around 120 people and has a number of patents and scientific publications to its name in recent years. The company collaborates with many renowned institutions and research facilities worldwide to find the best possible solutions in drug development. In summary, Concert Pharmaceuticals Inc is a very innovative company in the field of drug development. In addition to neurological research, the company also has projects in other areas. With its unique business model and the use of patented technologies, Concert Pharmaceuticals has the potential to develop new and effective drugs in the future, thereby improving the lives of many people worldwide. Concert Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Concert Pharmaceuticals's P/S Ratio

Concert Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Concert Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Concert Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Concert Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Concert Pharmaceuticals stock

What is the price-to-earnings ratio of Concert Pharmaceuticals?

The price-earnings ratio of Concert Pharmaceuticals is currently 8.89.

How has the price-earnings ratio of Concert Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Concert Pharmaceuticals has increased by 0% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Concert Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Concert Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Concert Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Concert Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Concert Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Concert Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Concert Pharmaceuticals?

Some factors that influence the price-earnings ratio of Concert Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Concert Pharmaceuticals pay?

Over the past 12 months, Concert Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Concert Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Concert Pharmaceuticals?

The current dividend yield of Concert Pharmaceuticals is .

When does Concert Pharmaceuticals pay dividends?

Concert Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Concert Pharmaceuticals?

Concert Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Concert Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Concert Pharmaceuticals located?

Concert Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Concert Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Concert Pharmaceuticals from 12/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/30/2024.

When did Concert Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/30/2024.

What was the dividend of Concert Pharmaceuticals in the year 2023?

In the year 2023, Concert Pharmaceuticals distributed 0 USD as dividends.

In which currency does Concert Pharmaceuticals pay out the dividend?

The dividends of Concert Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Concert Pharmaceuticals

Our stock analysis for Concert Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Concert Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.